Oct 30, 2026
Articles
Research Article
Systematic Reviews and Meta Analysis
Review Article
The European Journal of Rhinology and Allergy aims to publish high-quality research that contributes to the advancement of scientific knowledge and clinical practice in the fields of rhinology and allergy. The journal welcomes original and innovative studies of significant scientific and clinical value.
It is intended for healthcare professionals, physicians, researchers and other specialists with an academic or professional interest in these fields.
The European Journal of Rhinology and Allergy covers a wide variety of subjects related to rhinology and allergy. It publishes articles on clinical and basic research, case reports, review articles, technical notes, letters to the editor, 'Images of Interest' and quiz cases in these fields.
Manuscripts submitted for evaluation should be original and not previously presented or published in any electronic or print medium. If a manuscript was previously presented at a conference or meeting, authors should provide detailed information about the event, including the name, date, and location of the organization.
Manuscripts should be prepared in accordance with ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in January 2025).
Authors are required to prepare manuscripts in accordance with the relevant guideline listed below:
· Randomized research studies and clinical trials: CONSORT guidelines (for protocols, please see the SPIRIT guidance)
· Observational original research studies: STROBE guidelines
· Studies on diagnostic accuracy: STARD guidelines
· Systematic reviews and meta-analysis: PRISMA guidelines (for protocols, please see the PRISMA-P guidelines)
· Experimental animal studies: ARRIVE guidelines and Guide for the Care and Use of Laboratory Animals, 8th edition
· Nonrandomized evaluations of behavioral and public health interventions: TREND guidelines
· Case report: the CARE case report guidelines
· Genetic association studies: STREGA
· Qualitative research: SRQR guidelines
To find the right guideline for your research, please complete the questionnaire by Equator Networkhere.
European Journal of Rhinology and Allergy encourages authors to follow the ‘Sex and Gender Equity in Research – SAGER – guidelines’ when preparing their manuscripts to promote the inclusion of sex and gender considerations in research. Before submission, authors can consult EASE Guidelines for Authors and Translators to produce clear, concise and accurate manuscripts that are easy to understand and free of common errors and pitfalls.
The style of manuscripts should follow the AMA Manual of Style, 11th Edition.
Manuscripts can only be submitted through the journal’s online manuscript submission and evaluation system. Manuscripts submitted via any other medium and submissions by anyone other than one of the authors will not be evaluated.
In addition to the manuscript files, authors are required to submit the following during the initial submission:
· Copyright Agreement and Acknowledgement of Authorship Form, and
· ICMJE Disclosure Form (should be filled in by all contributing authors).
Preparation of the Manuscript
Title page: A separate title page should be submitted with all submissions and this page should include:
· The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
· Name(s), affiliations, highest academic degree(s), and ORCID IDs of the author(s),
· Grant information and detailed information on the other sources of support,
· Name, address, telephone (including the mobile phone number), and email address of the corresponding author,
· Acknowledgment of the individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria.
· If the author(s) is a member of the journal's Editorial Board, this should be specified in the title page.
Abstract: An abstract should be submitted with all submissions except for Letter to the Editor. The abstract of Research Articles and Study Protocols should be structured with subheadings (Objective, Methods, Results, and Conclusion).
Keywords: Each submission must be accompanied by a minimum of three to a maximum of six keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (https://www.nlm.nih.gov/mesh/MBrowser.html).
Main Points: All submissions except letters to the editor should be accompanied by 3 to 5 “main points.” These main points should highlight the most important results of the study and emphasize the main message of the manuscript. The main points should be structured as a list and should be written in a clear and straightforward manner. Since the main points are intended for experts and specialists in the field, they should be written in plain language that is easy to understand. By including main points with the manuscript, authors can help ensure that the most important findings and messages of their study are conveyed clearly to the reader.
MANUSCRIPT TYPES
Original Articles: Research articles provide new information based on original research. The acceptance of research articles is typically based on the originality and importance of the research. The main text of a Research Article should be structured with subheadings, including Introduction, Methods, Results, Discussion, and Conclusion.
Clinical Trials: European Journal of Rhinology and Allergy adopts the ICMJE's clinical trial registration policy, which requires that clinical trials must be registered in a publicly accessible registry that is a primary register of the WHO International Trials Registry Platform (ICTRP) or in ClinicalTrials.gov. By registering clinical trials in a publicly accessible registry, authors can help to promote transparency and accountability in their research.
Instructions for the clinical trials are listed below.
• Clinical trial registry is only required for the prospective research projects that study the relationship between a health-related intervention and an outcome by assigning people to different groups.
• To have their manuscript evaluated in the journal, authors should register their research to a public registry at or before the time of first patient enrollment.
• Based on most up to date ICMJE recommendations, European Journal of Rhinology and Allergy accepts public registries that include minimum acceptable 24-item trial registration dataset.
• Authors are required to state a data sharing plan for the clinical trial registration. Please see details under the “Data Sharing” section.
• For further details, please check ICMJE Clinical Trial Policy and COPE Data and Reproducibility guidelines.
Reporting Statistical Analysis
Statistical analysis to support conclusions is usually necessary. Statistical analyses must be conducted in accordance with international statistical reporting standards (Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. Br Med J 1983: 7; 1489-93). Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used during the process must be specified.
When reporting statistical data in a research paper, it is important to present the values in a clear and consistent manner. P values, confidence intervals (CIs), and other statistical measures should be rounded appropriately and expressed according to the guidelines provided. For example, P values should be expressed to two digits to the right of the decimal point unless the first two digits are zeros, in which case three digits should be provided (eg, instead of P < .01, report as P = .002). However, values close to .05 may be reported to three decimal places because .05 is an arbitrary cut-off point for statistical significance (eg, P = .053). P values less than .001 should be designated as P < .001 rather than providing the exact value (eg, P = .000006).
Units should be prepared in accordance with the International System of Units (SI).
Review Articles: Review articles that are written by authors with extensive knowledge and expertise in a particular field and a strong track record of publication are welcomed. These authors may even be invited to contribute a review article to the journal. Review articles should provide a comprehensive overview of the current state of knowledge on a topic in clinical practice, and should include discussions and evaluations of relevant research. The subheadings of the review articles can be planned by the authors. Please check Table 1 for the limitations for Review Articles.
Case Reports: The journal has limited space for case reports, and prioritizes publishing reports on rare cases or challenging conditions that provide new insights into diagnosis and treatment, offer novel therapies, or reveal knowledge not yet included in the literature. Interesting and educational case reports are also welcomed for publication. The text of a case report should include Introduction, Case Presentation, and Discussion sections. An unstructured abstract should also be included. Please check Table 1 for the limitations for Case Reports.
Letter to the editor: A "Letter to the Editor" is a type of manuscript that discusses important or overlooked aspects of a previously published article. This type of manuscript may also present articles on topics within the scope of the journal that are of interest to readers, particularly educational cases. Additionally, readers may use the "Letter to the Editor" format to share comments on published manuscripts.
Key Features:
- The "Letter to the Editor" should be unstructured and should not include an abstract, keywords, tables, figures, images, or other media.
- The manuscript being commented on must be properly cited within the "Letter to the Editor."
- Our journal considers all feedback on published articles. However, we emphasize that comments should be scientifically relevant and meaningful to the discussion. Irrelevant or unfounded comments may be rejected.
ICMJE Guidelines:
Our journal adheres to the guidelines set forth by the ICMJE (International Committee of Medical Journal Editors). According to ICMJE, "Letters to the Editor" should be a platform for responsible debate, critique, and discussion. These letters may raise substantial criticisms or questions about previously published articles, and authors of the discussed articles are expected to respond to these criticisms.
ICMJE also notes that editors have the right to edit these letters for length, grammar, and style. However, all letters should contribute constructively to the academic discussion and critique, and those deemed irrelevant or unfounded may be rejected.
You can view the ICMJE guidelines on "Correspondence" here.
Quiz Case: This type of article aims to illustrate clinical conditions with visual materials. The manuscript should consist of 3 main sections: 1) The introudcution praragraph the clinical scenario, 2) A question with one correct and three incorrect answers, 3) Discussion of the correct answer and the explanation for incorrect answers. Since images and other visual materials are the vital part of quiz case, the images should be in high resolution. For photographs that may reveal the identity of the patients, authors are required to obtain publication consents from their patients or the parents/legal guardians of the patients.
Images of Interest: This type of submissions should present a striking image that may challenge and inform readers and contribute to their education. Please check Table 1 for the limitations for Images of Interest.
Table 1. Limitations for each manuscript type.
Type of manuscript | Wordlimit | Abstract word limit | Reference limit | Table limit | Figure limit |
| Original Article | 3000-4000 | 250 (Structured) | 30-40 | 6 | 7 or total of 15 images |
| Review Article | 5000-6000 | 250 | 50-60 | 6 | 10 or total of 20 images |
| Technical Note | 1500 | No abstract | 15 | No tables | 10 or total of 20 images |
| Case Report | 1000 | 200 | 15-20 | No tables | 10 or total of 20 images |
| Letter to the Editor | 500-1000 | No abstract | 5 | No tables | No media |
| Image of Interest | 500 | No abstract | 5 | No tables | 4 or total of 8 images |
| Quiz Case | 700 | No abstract | N/A | No tables | 8-10 |
*Word limit should not include the abstract, references, tables, and figure legends.
Tables
Tables should be included in the main document, after the reference list, and they should be numbered consecutively in the order they are referred to within the text. Each table should have a descriptive title placed above it, and any abbreviations used in the table should be defined below the table by footnotes (even if they are defined in the main text). Tables should be created using the "insert table" command of the Word processing software, and they should be arranged clearly to make the data easy to read and understand. The data presented in the tables should not be a repetition of the data presented in the main text, but should support and enhance the main text.
Figures and Figure Legends
Figures should be submitted as separate files in TIFF or JPEG format, and they should not be embedded in the Word document or the main manuscript file. If a figure has subunits, each subunit should be submitted as a separate file, and the subunits should not be merged into a single image. The figures should not be labeled (a, b, c, etc.) to indicate subunits. Instead, the figure legend should be used to describe the different parts of the figure. Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends.Images should be anonymized to remove any information that may identify individuals or institutions. The minimum resolution of each figure should be 300 DPI, and the figures should be clear and easy to read. Figure legends should be listed at the end of the main document. Figures should be referred to within the main text, and they should be numbered consecutively in the order in which they are mentioned.
Abbreviations
All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition, and it should be used consistently throughout the paper.
Identifying products
When mentioning a drug, product, hardware, or software program in a manuscript, it is important to provide detailed information about the product in parentheses. This should include the name of the product, the producer of the product, and the city and country of the company. For example, if mentioning a Discovery St PET/CT scanner produced by General Electric in Milwaukee, Wisconsin, USA, the information should be presented in the following format: "Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)." Providing this information helps to ensure that the product is properly identified and credited.
Supplementary Materials
Supplementary materials, including audio files, videos, datasets, and additional documents (e.g., appendices, additional figures, tables), are intended to complement the main text of the manuscript. These supplementary materials should be submitted as a separate section after the references list. Concise descriptions of each supplementary material should be included to explain their relevance to the manuscript. Page numbers are not required for supplementary materials.
REFERENCES
Both in-text citations and the references must be prepared according to the AMA Manual of Style 11th Edition.
When citing publications, preference should be given to the latest, most up-to-date sources. Citing the latest sources can help to ensure that the paper is relevant and timely, and that it reflects the latest developments in the field.
It is the responsibility of the authors to ensure the accuracy of the references in their article. All sources must be properly cited, and the citations must be formatted correctly.
In the main text of the manuscript, references should be cited in superscript after punctuation.
If an ahead-of-print publication is cited, the DOI number should be provided in the reference list.
Journal titles should be abbreviated in the reference list in accordance with the journal abbreviations in Index Medicus/MEDLINE/PubMed.
When there are six or fewer authors, all authors should be listed. If there are seven or more authors, the first three authors should be listed followed by “et al.” in the reference list.
The reference styles for different types of publications are presented in the following examples.
Journal Article: Ammitzboll C, Andersen JB, Vils SR, et al. Isolation, behavioral changes, and low seroprevalence of SARS-CoV-2 antibodies in patients with systemic lupus erythematosus or rheumatoid arthritis. Arthritis Care Res. 2022;74(11):1780-1785.
Book Section: Cohen EL. The multidisciplinary, interdisciplinary, and transdisciplinary nature of health communication scholarship. In: Thompson TL, Harrington NG, eds. The Routledge Handbook of Health Communication. London: Routledge;2022:3-16.
Books with a Single Author: Haslwanter T. An Introduction to Statistics with Python. 2nd ed. New York, NY: Springer International Publishing; 2022.
Editor(s) as Author: Thompson TL, Harrington NG, eds. The Routledge Handbook of Health Communication. London: Routledge;2022.
Thesis: Chunga A. The Role of the Gastrointestinal Tract Microbiota in Colonisation Resistance Against Common Enteric Pathogens in Malawian Children. Dissertation. University of Liverpool; 2022.
Websites: International Society for Infectious Diseases. ProMed-mail. Accessed December 13, 2022. http://www.promedmail.org
Epub Ahead of Print Articles: Torres X, Bennasar M, Bautista-Rodríguez C, et al. The heart after surviving twin-to-twin transfusion syndrome. Am J Obstet Gynecol. 2022 Mar 26. doi: 10.1016/j.ajog.2022.03.049. [Epub ahead of print].
DISCLAIMER
The statements or opinions expressed in the manuscripts published in the journal reflect the views of the author(s) and not the views of the editors, editorial board, and/or publisher. The editors, editorial board, and publisher are not responsible for the content of the manuscripts and do not necessarily endorse the views expressed in them. It is the responsibility of the authors to ensure that their work is accurate and well-researched, and the views expressed in their manuscripts are their own. The editors, editorial board, and publisher simply provide a platform for the authors to share their work with the scientific community.
PUBLICATION ETHICS
European Journal of Rhinology and Allergy aims to adhere to the guidelines and core practices set forth by several organizations, including the Committee on Publication Ethics (COPE) guidelines, the Principles of Transparency and Best Practice in Scholarly Publishing (a joint statement by COPE, DOAJ, OASPA and WAME), and the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals by the ICMJE. These guidelines and recommendations are designed to promote transparency, integrity, and best practices in scholarly publishing.
Medical research involving human subjects, including research on identifiable human material and data, should follow the WMA Declaration of Helsinki, which provides guidance on obtaining informed consent from participants, protecting their privacy and confidentiality, and avoiding harm to study participants.
The journal also adheres to the WAME Recommendations on Publication Ethics Policies for Medical Journals, which provide guidance on handling conflicts of interest, dealing with suspected research misconduct, and ensuring the integrity and transparency of the peer review process.
Authors are advised to use the EASE Ethics Checklist for Authors to ensure that their manuscripts comply with ethical standards and practices.
RESEARCH ETHICS
European Journal of Rhinology and Allergy adheres to national and international standards of research and publication ethics. All submitted and published studies must be conducted in full compliance with the established principles of research ethics. In this context, compliance with national and international ethical standards is mandatory for research involving human and animal participants. For studies involving human participants, informed consent must be obtained.
For studies requiring ethics committee approval, details of the approval must be included in the text (committee name, date, and reference number). Authors must adhere to the principles of scientific integrity when collecting, analysing, and reporting data. Plagiarism, data fabrication, data manipulation and other ethical violations will not be tolerated.
ARTIFICIAL INTELLIGENCE (AI) POLICY
The Role of AI in Manuscript Preparation
European Journal of Rhinology and Allergy follows the position of the Committee on Publication Ethics (COPE) and the WAME Recommendations on Chatbots and Generative Artificial Intelligence in Relation to Scholarly Publications with regard to the use of AI and AI-assisted technology in manuscript preparation.
Use of AI tools and transparency. AI tools may only be used for limited tasks, such as language editing and technical data processing. All such use must be clearly declared in the manuscript, specifying the tool’s name, version, and the exact purpose for which it was used. AI tools, and articles generated or written by AI tools, cannot be cited as authoritative sources or references within the manuscript. Authors retain sole responsibility for the final content of the manuscript. All AI-generated output must be rigorously audited for factual errors, “hallucinations,” and algorithmic bias before submission.
Authorship and accountability. Authorship encompasses a range of tasks that can only be performed by humans, and authors are accountable for ensuring the article’s originality and for possessing the requisite qualifications for authorship. While AI can be employed for language corrections during the writing of an article (and this should be explicitly stated in the article), it cannot be included as an author. Authors must take full responsibility for all aspects of the manuscript, including data collection, analysis, interpretation, and writing. AI tools cannot be used to delegate this responsibility. Authors are responsible for the accuracy and reliability of all claims and conclusions in the manuscript.
Declaration of AI Usage
Authors who use AI or AI-assisted technologies in the production of their manuscript must provide a disclosure as follows.
Title page and cover letter: Authors must declare the use of AI tools on the title page and in the cover letter submitted at the time of manuscript submission. Depending on the case, authors may use one of the following statements:
– The author(s) declared that no AI and/or LLM tool was used in the preparation of this manuscript.
– The author(s) declared that [name of the tool/service] was used and/or employed to [reason]. The author(s) confirm and acknowledge that the declared usage in the preparation, submission and publication (if accepted) of the study aligns with the journal’s policies. The author(s) acknowledge that they are responsible and accountable for the content published in the study.
Materials and Methods: The specific tool name, version, and the purpose of its use (e.g., “for literature search,” “for grammatical improvement,” or “for image processing”) must be clearly stated in the Materials and Methods section of the paper. For example: “AI and/or LLM [tool – version – producer] was used in this study for [e.g., grammatical improvement].”
Data and Research Integrity
- Fact-checking: Authors must independently verify that all citations, clinical data, and medical claims generated by AI are accurate and are not “hallucinations.”
- Originality: Authors must ensure that AI usage does not constitute plagiarism. The final submitted text must be the original contribution of the authors.
- Data integrity: Authors must ensure that no sensitive or identifiable patient data is uploaded to any AI tool, as these systems may not guarantee confidentiality.
AI Use in Peer Review and the Editorial Process
The journal’s policy may allow editors and reviewers to use large language model (LLM) tools for certain tasks in their review processes, such as language editing, accuracy checking of raw and/or bulk data, research integrity tools, and detection of paper mills and/or unusual activity. To protect the confidentiality of the submission and the intellectual property of the authors:
- Reviewers and editors are advised against uploading any part of a submitted, unpublished manuscript to an AI tool or LLM, to ensure data privacy.
- Any use of AI tools for administrative tasks (e.g., grammar checking) during the review process must be explicitly approved by the editorial office and must not involve sharing the manuscript text with third-party servers.
Image Generation and Copyright
The journal is committed to upholding existing copyright laws and recognized best practices in publication ethics. Due to ongoing legal uncertainties surrounding AI-generated visual content, the use of such material in the journal’s publications is generally not permitted, except in the following cases:
- Licensed content from agencies: Images or artwork sourced from agencies with which the journal has contractual agreements, provided the content was created in a legally and ethically sound manner.
- Content discussing AI: Visual or video content that is directly referenced in an article focused on artificial intelligence. These cases are reviewed individually.
All approved exceptions must be clearly labeled as “AI-generated” within the image or figure caption.
Authors must verify the accuracy and appropriateness of images generated by AI, and clearly state the AI methodology used within the manuscript. Any AI-generated content must comply with scientific standards and ethical guidelines.
Human Responsibility, Data Privacy and Legal Compliance
Authors are fully accountable for the integrity of their work. When using AI tools, authors, reviewers and editors must adhere to the following standards to protect research ethics and intellectual property.
- Data confidentiality and privacy: Before using any AI tool, authors, reviewers and editors must review its Terms of Service to ensure that their data, inputs, and unpublished manuscripts are kept private and secure. Inputting personally identifiable information or sensitive research data into any system that does not provide adequate confidentiality guarantees is strictly prohibited.
- Intellectual property and rights: Authors, reviewers and editors must ensure that they do not grant AI service providers ownership rights or permissions to use their input data for model training or any other secondary purposes. They must also confirm that the tool’s usage terms do not impose restrictions that could hinder the subsequent publication, copyright, or dissemination of the research.
- Content restrictions: AI tools must not be used to generate content that infringes upon third-party rights. This includes, but is not limited to:
– Images that duplicate or reference existing copyrighted material, brands, or trademarks.
– Content depicting identifiable real individuals without authorization.
– Replication of an individual’s voice or likeness.
- Accuracy, ethics and research integrity: Authors retain sole responsibility for the final content of the manuscript. All AI-generated output must be rigorously audited for factual errors, “hallucinations,” and algorithmic bias before submission.
PERMISSION POLICY
As of the April 2020 issue, the journal’s content is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
Under this license, users are allowed to share, adapt, reproduce and distribute the journal’s content for non-commercial purposes, provided that they give appropriate credit to the original author and the journal.
The Turkish Rhinologic Society is the copyright holder of content published before April 2020. The commercial use of the journal’s content requires permission from the Turkish Rhinologic Society, which may be subject to fees or restrictions.
SELF-ARCHIVING POLICY
Authors retain the right to self-archive their work on their institutional or personal websites, as well as in open access repositories, after publication. It is expected that authors appropriately acknowledge the original publication and include the DOI number when sharing their articles. Additionally, authors are requested to provide a link from the deposited version to the URL of the publisher’s website. This requirement is intended to safeguard the integrity and authenticity of the scientific record, with the online published version on the publisher’s website clearly identified as the definitive version of record.
ADVERTISING POLICY
European Journal of Rhinology and Allergy accepts digital advertisements on its website. These ads must be approved by the journal’s Editorial Board and management, and must be clearly labeled as advertisements. Advertisers have no influence on editorial decisions or advertising policies.
Those interested in advertising in the journal should contact the Editorial Office.
AUTHORSHIP
All individuals listed as an author should meet the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship is based on the following four criteria:
1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work.
2. Drafting the work or reviewing it critically for important intellectual content.
3. Final approval of the version to be published.
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
In addition to being accountable for the parts of the work they have done, authors should be able to identify which co-authors are responsible for specific other parts of the work, so that the contributions of all authors are accurately and appropriately acknowledged. Authors may use CRediT (Contributor Roles Taxonomy) to provide information about individual contributions at the time of submission. It is expected that all authors agree upon their individual contributions as shared by the corresponding author. The authors’ contribution statement will be published with the final article and should accurately reflect contributions to the work.
Authors should also have confidence in the integrity of the contributions of their co-authors: that the research was conducted in an ethical and responsible manner, and that the data and results presented in the manuscript are accurate and reliable.
Individuals who do not meet all four authorship criteria should not be listed as authors. They can, however, be acknowledged on the title page of the manuscript, to recognize their contributions and to provide transparency about who was involved in the research.
If the Editorial Board suspects a case of ghost, honorary or gift authorship, the submission will be suspended and the relevant COPE flowchart and COPE policy on authorship and contributorship will be followed.
Change of Authorship
Any request for a change to authorship, such as the removal or addition of authors or a change in the order of authors, should be submitted to the editorial office with a letter stating the reasons for the change. The letter must be signed by all authors, including any who have been removed.
The Editorial Board handles all requests for changes to authorship in a consistent and transparent manner, following the relevant COPE flowchart guidelines. These procedures are in place to protect the integrity of the research and the reputation of all involved authors.
POST-PUBLICATION CORRECTION REQUESTS AND RETRACTIONS
All post-publication correction requests are subject to editorial review. The Editorial Board reviews the request and determines whether a correction is necessary and appropriate. The decision to publish a correction is based on the nature of the error, its potential impact on the article, and the availability of supporting evidence. The Editorial Board may consult the authors, reviewers, and other experts as needed. If the request is approved, the article is corrected in the journal’s archive.
The Editorial Board reviews cases following journal policies, ICMJE and COPE guidelines.
If misconduct allegations are made by whistleblowers directly, the Editorial Board follows the relevant COPE flowchart. The journal acts in accordance with the COPE flowchart on how to respond to whistleblowers when concerns about a published article are raised on a social media site.
In some cases, an ombudsperson may be assigned to resolve claims that cannot be resolved internally.
To investigate potential ethical misconduct, the Editorial Board may share information with other editors-in-chief, following the relevant COPE recommendations. If necessary, the journal may also contact institutions to inform them of suspected misconduct by researchers and provide evidence to support these concerns, following COPE guidelines.
In the event of ethical misconduct concerns, the editors investigate the case according to COPE retraction guidelines. If the investigation verifies the concern, the editors may issue a retraction notice. The retraction notice is published in the journal and the article’s record is updated to reflect the retraction. The article remains in the journal’s archive but is clearly marked as retracted. The article’s record is also updated in the relevant indexes.
PLAGIARISM AND ETHICAL MISCONDUCT
All submissions are screened by similarity detection software (Crossref Similarity Check powered by iThenticate) during the peer-review and/or production processes.
When discussing others’ (or one’s own) previous work, authors must cite the material correctly in every instance. Authors are strongly advised to avoid any form of plagiarism and ethical misconduct, examples of which are given below.
• Citation manipulation: Manipulating the number of citations received by an author, journal, or other publication through means such as excessive self-citation, excessive citation of articles from the same journal, honorary citations, or citation stacking.
• Self-plagiarism (text recycling): Using overlapping sections or sentences from the author’s previous publications without proper citation.
• Salami slicing: Using the same data from a research study in several different articles, reporting the same hypotheses, population, and methods in multiple papers.
• Data fabrication: Adding data that never occurred during data gathering or experiments.
• Data manipulation/falsification: Manipulating research data with the intention of giving a false impression, including manipulating images, removing outliers or “inconvenient” results, or changing data points.
In the event of alleged or suspected research misconduct such as plagiarism, citation manipulation, or data falsification/fabrication, the Editorial Board will follow the appropriate COPE flowcharts to ensure that the allegations or suspicions are handled in a fair, transparent, and consistent manner.
WITHDRAWAL REQUESTS
Withdrawal requests for an article are reviewed by the Editorial Board. To request the withdrawal of an article, the authors must send a letter signed by all authors, stating their request and the reasons for withdrawal, to the journal editor. Withdrawal requests are addressed promptly, and authors who submit a request in good faith may consider their manuscript withdrawn if they have not received a response within a reasonable time frame, even without formal confirmation from the journal.
Authors should not submit their work to another journal for evaluation until they have officially withdrawn their manuscript, that is, after submitting their request and allowing a reasonable period for the journal to respond. This avoids potential conflicts of interest and duplicate publication.
DECLARATION OF INTERESTS
European Journal of Rhinology and Allergy requires the ICMJE Disclosure Form to be completed and submitted by all contributing authors of each manuscript, so that the journal is informed about potential conflicts of interest.
The journal also requires and encourages individuals involved in the peer review process of submitted manuscripts to disclose any existing or potential competing interests that might lead to bias.
The Editorial Board handles cases of potential competing interests of editors, authors, or reviewers within the scope of the relevant COPE flowcharts and ICMJE recommendations.
FINANCIAL DISCLOSURE
European Journal of Rhinology and Allergy requires authors to disclose any financial support they received to conduct their research. This information should be included in the funding statement provided when the manuscript is submitted to the journal.
The funding statement should include the name of any granting agencies, the grant numbers, and a description of each funder’s role in the research. If the funder had no role in the research, this should be stated in the funding statement as well. This information helps readers understand the potential biases and conflicts of interest that may exist in the research.
PREPRINT POLICY
European Journal of Rhinology and Allergy does not consider preprints as prior publication, which means that authors are allowed to present and discuss their findings on a non-commercial preprint server before submitting their work to the journal.
However, authors must provide the journal with the preprint server deposition of their article, along with its DOI, during the initial submission process.
If the article is accepted and published in the journal, it is the responsibility of the authors to update the archived preprint and link it to the published version of the article. This helps ensure that readers can easily access the most up-to-date and accurate information.
DATA SHARING POLICY
As of 1 January 2019, a data sharing statement is required for the registration of clinical trials. Authors are required to provide a data sharing statement for articles that report the results of a clinical trial. According to the ICMJE data sharing policy, the statement should indicate:
- Whether individual deidentified participant data will be shared
- What data in particular will be made available
- Whether additional, related documents will also be provided
- When the data will become accessible and for how long it will remain available
- The criteria for accessing the data, including who will have access, the purpose of the analysis, and the mechanism for obtaining the data
Authors are recommended to check the ICMJE data sharing examples.
When submitting a clinical trial to European Journal of Rhinology and Allergy:
- Authors are required to register the trial in a publicly accessible registry according to ICMJE recommendations and the instructions above.
- The name of the registry and the registration number should be provided on the title page at initial submission.
- The data sharing statement should also be provided on the title page, even if the authors do not plan to share their data.
The clinical trial and data sharing policy of the journal is valid for articles submitted from June 2023.
APPEALS AND COMPLAINTS
The Editorial Board is responsible for addressing appeals and complaints in accordance with the guidelines and recommendations of COPE. An author with an appeal or complaint should contact the editorial office directly to discuss their concerns. The Editorial Board reviews the case and makes a decision based on COPE guidelines.
The Editor in Chief has the final authority in the decision-making process for all appeals and complaints. In some cases, an ombudsperson may be assigned to resolve claims that cannot be resolved internally. The journal follows a fair and transparent process for handling appeals and complaints, with the goal of preserving the integrity of the scientific record.
INCLUSION AND DIVERSITY POLICY
To help reduce bias in scholarly publishing, European Journal of Rhinology and Allergy accepts and supports the Joint Commitment for Action on Inclusion and Diversity in Publishing by applying its Minimum Standards on Inclusion and Diversity in its organizational framework and editorial processes.
SEX AND GENDER POLICY
European Journal of Rhinology and Allergy contributes to sex and gender equity in research and publication by applying the Sex and Gender Equity in Research (SAGER) guidelines in its editorial decision and review processes. Manuscripts that are discordant with these guidelines may be rejected.
DISCLAIMER
The statements or opinions expressed in the manuscripts published in the journal reflect the views of the author(s) and not the views of the editors, Editorial Board, and/or publisher. The editors, Editorial Board, and publisher are not responsible for the content of the manuscripts and do not necessarily endorse the views expressed in them. It is the responsibility of the authors to ensure that their work is accurate and well researched, and the views expressed in their manuscripts are their own. The editors, Editorial Board, and publisher simply provide a platform for the authors to share their work with the scientific community.